Clinical Trials Logo

Filter by:
NCT ID: NCT02882412 Recruiting - Chronic Pain Clinical Trials

Effectiveness of Buprenorphine/Naloxone

Start date: March 2016
Phase:
Study type: Observational

Long-term use of opioids for chronic pain is a growing health and social problem, mainly because of the risk of dependence. Buprenorphine/naloxone is used as substitution therapy for opioid dependence. This substitution therapy in patients with opioid dependence lessens withdrawal symptoms and craving. There is limited research on the effectiveness of buprenorphine/naloxone in patients with chronic pain and iatrogenic opioid dependence. The primary aim of this study is to investigate the effectiveness of buprenorphine/naloxone in patients suffering from chronic pain and an iatrogenic induced dependence on opioids. This study will investigate the effects of opioid substitution by buprenorphine/naloxone in patients suffering from chronic pain using long-term opioids, with pain and withdrawal symptoms as primary outcome measures. Secondary outcome measures will be craving, substance use, psychiatric comorbidity and quality of life.

NCT ID: NCT02881840 Completed - Clinical trials for Post-operative Nausea and Vomiting

Mass-balance Study of [14C]-APD421 in Healthy Volunteers

Start date: August 2016
Phase: Phase 1
Study type: Interventional

Open-label, non-randomised, single dose study in 6 healthy male subjects to assess the mass balance recovery, metabolite profile, metabolite identification and pharmacokinetics of 14C-labelled APD421

NCT ID: NCT02881359 Active, not recruiting - Anastomotic Leakage Clinical Trials

SEAL Registry - European Registry for the Effectiveness of LifeSeal® Kit

Start date: October 2016
Phase:
Study type: Observational [Patient Registry]

This study will assess the effectiveness of commercially available LifeSeal® Kit as measured by the incidence of post-operative clinical anastomotic leak rates in subjects undergoing low and ultralow anterior resection with an anastomosis. All patients treated with LifeSeal® will be offered to participate

NCT ID: NCT02880956 Completed - Alzheimer's Disease Clinical Trials

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Start date: January 26, 2017
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).

NCT ID: NCT02880722 Completed - Clinical trials for Irritable Bowel Syndrome

Experience Sampling Method for Symptom Assessment in Irritable Bowel Syndrome

Start date: October 2016
Phase:
Study type: Observational

Reliable patient reported outcome measures (PROM's) for symptom assessment in irritable bowel syndrome are essential in order to investigate natural disease course and potential treatment options aimed at symptom improvement, since biological markers are currently unavailable. Currently used symptom assessment methods, i.e. end-of-day or end-of-week questionnaires, have considerable limitations. The Experience Sampling Method (ESM), an electronic questioning method characterized by random and repeated, momentary assessments in the subject's current state and environment, might overcome these limitations. Aim of this study is to validate an IBS-specific electronic patient-reported outcome measure, based on the Experience Sampling Method-principle, for symptom assessment in IBS.

NCT ID: NCT02880631 Recruiting - Hypertension Clinical Trials

BAROSTIM THERAPY™ In Resistant Hypertension

Start date: December 13, 2016
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.

NCT ID: NCT02879448 Active, not recruiting - Stroke Clinical Trials

AMPLATZER™ Amulet™ LAA Occluder Trial

Amulet IDE
Start date: August 24, 2016
Phase: N/A
Study type: Interventional

The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the Amulet device or the WATCHMAN device and will be followed for 5 years after device implant.

NCT ID: NCT02879383 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the efficacy and safety of the Fractyl duodenal mucosal resurfacing (DMR) Procedure using the Revita System compared to a sham procedure for the treatment of uncontrolled type 2 diabetes. Subjects randomized to the DMR procedure are followed per protocol for 48 Weeks. The Sham treatment arm will cross over to receive the DMR treatment at 24 weeks with background medications held constant from 24-48 weeks of follow up.

NCT ID: NCT02879305 Completed - Anaemia Clinical Trials

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Start date: September 28, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.

NCT ID: NCT02878434 Recruiting - Cancer Clinical Trials

Fertility Preservation in Young Women With Cancer

Start date: May 23, 2017
Phase:
Study type: Observational [Patient Registry]

The researchers aim to record the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded. Study population: All patients with a cancer for whom a fertility preserving cancer treatment is applied. The results of the study population are compared to young women undergoing standard cancer treatment.